Skip to content

REDUCE Trial: Perineural Dexamethasone on Scalp Nerve Blocks

REDUCE Trial: The Effects of Perineural Dexamethasone on Scalp Nerve Blocks for Relief of Postcraniotomy Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04648358
Enrollment
156
Registered
2020-12-01
Start date
2020-12-13
Completion date
2023-01-02
Last updated
2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniotomy, Dexamethasone, Postoperative Pain, Scalp Nerve Blocks

Brief summary

Pain is common in the first 2 days after major craniotomy. Inadequate analgesia may lead to an increased risk of postoperative complications. Most pain following craniotomy arises from the pericranial muscles and soft tissues of the scalp. Scalp nerve blocks with local anesthesia seem to provide effective, safe, however transient postoperative analgesia which does not seem to meet the requirements of craniotomy. Currently, peripheral dexamethasone has been observed to significantly prolong the duration of analgesia of nerve blocks (e.g., saphenous nerve block, adductor canal block, thoracic paravertebral block, brachial plexus nerve block). On the contrary, a study reported that perineural dexamethasone did not appear to prolong the analgesic time after supratentorial craniotomy. However, all patients in this study were given 24 mg of oral or intravenous dexamethasone regularly at least 7 days during the perioperative period, which possibly masked the role of single local low doses of perineural dexamethasone. Therefore, the analgesic effect of single dexamethasone for scalp nerve blocks without the backdrop of perioperative glucocorticoid deserves further clarification.

Interventions

DRUGBupivacaine

The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

DRUGDexamethasone combined with bupivacaine

The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* scheduled for elective supratentorial craniotomy under general anesthesia; * age 18 to 64 years; * an American Society of Anesthesiologists (ASA) physical status of I, II or III; * preoperative Glasgow Coma Scale (GCS) score of 15/15.

Exclusion criteria

* History of chronic headache or chronic pain syndrome of any cause, psychiatric disorders, or uncontrolled epilepsy; * Inability to understand or use the pain scales before surgery; * Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 hours before surgery; * Request of oral/intravenous glucocorticoid to decrease cerebral edema within 1 week before surgery; * Pregnancy or breastfeeding; * Extreme body mass index (BMI) (\< 15 or \> 35); * Participation in another interventional trial that interferes with the intervention or outcome of this trial; * Refusal or inability of the patient and/or legal guardian to provide informed consent; * Coagulopathy; * Infection around the puncture point; * History of allergies to any of the study drugs.

Design outcomes

Primary

MeasureTime frameDescription
The duration of analgesiaWithin 48 hours after surgeryThe time between the performance of the block and the administration of the first press the PCA demand button postoperatively.

Secondary

MeasureTime frameDescription
Numeric rating scale (NRS)At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperativelyNRS: 11-point scale in which 0 = no pain to 10 = worst imaginable pain. An NRS score ≥4 will be considered significant or moderate pain. An NRS score ≥7 will be considered severe pain. Meanwhile, the localization of the site of the pain will also be documented.
Glasgow Coma Scale (GCS)At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperativelyA scale for measuring level of consciousness, in which scoring is determined by three factors: amount of eye opening, verbal responsiveness, and motor responsiveness.
Postoperative nausea and vomiting (PONV)Within 48 hours after surgeryVomiting will be defined as the forceful expulsion of gastric contents, and nausea will be defined as an unpleasant sensation associated with the urge to vomit.
BradycardiaWithin 48 hours after surgeryBradycardia will be defined as HR\<60 beats/minute in at least two instances more than 5 minutes apart.
Sufentanil consumptionAt 4, 12, 24 and 48 hours postoperativelyThe cumulative amount of sufentanil consumption by PCA
Emergence deliriumWithin 48 hours after surgeryEmergence delirium will be assessed by the Sedation Agitation Scale (SAS), a 7-point scale on which a higher score represents greater agitation.
The length of stay (LOS)About at 2 weeks after surgeryThe LOS will be defined as the number of nights spent in the hospital after surgery.
Patient satisfaction score (PSS)At 2, 4, 8, 12, 16, 20, 24, and 48 hours postoperativelyPSS: 0 for unsatisfactory to 10 for very satisfactory.
HypotensionWithin 48 hours after surgeryHypotension will be defined as any of the following: systolic BP \<90 mm Hg for 5 minutes or a 35% decrease in mean arterial blood pressure.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026